Climate Change Data

Environmental Metrics

ESG Focus Areas

• Climate Change
• Environmental Protection
• Resource Management
• Employee Well-being
• Health and Safety
• Supply Chain Management
• Product Quality and Safety
• Responsible Marketing
• Anti-corruption
• Community Investment
• Intellectual Property Rights

Environmental Achievements

• Achieved 100% waste recycling and processing in 2023.
• Implemented various energy-saving measures, including variable frequency controls, multi-effect water distillators, active power filters, and reactive compensation technology.
• Installed rooftop photovoltaic power generation equipment in Shanghai Biotech Park.
• Used air-inflated faucets and infrared sensor flushing valves to reduce water consumption.
• Replaced conventional lighting with intelligent lighting systems in certain areas.
• Advocated for electronic documentation and encouraged employees to bring their own cups.

Social Achievements

• Commercialized PUYOUHENG (Pucotenlimab Injection) with sales revenue exceeding RMB100 million.
• Launched the “Puyou Lifetime – PUYOUHENG® Personal Assistance Project” to provide drug assistance to patients.
• Completed the tendering process on the procurement platform in 21 provinces, covering 76 cities.
• Successfully joined the Huimin Insurance in five locations.
• Organized various team-building activities for employees.
• Provided comprehensive employee training programs (719 sessions, 14,355.5 hours total).

Governance Achievements

• Established an ESG organizational structure covering all subsidiaries and departments.
• Implemented comprehensive internal control and risk management policies.
• Adopted whistleblowing and anti-corruption policies and systems.
• Maintained a zero-tolerance attitude towards corruption and bribery.
• Conducted regular employee performance assessments and evaluations.
• Established a transparent employee promotion pathway.

Climate Goals & Targets

Environmental Challenges

• Treatment of waste gas from experiments.
• Potential impacts of environmental and climate change risks on company operations.
• Intense competition and rapid technological change in the biopharmaceutical industry.
• Regulatory approval processes for drug candidates.
• Maintaining sufficient cash and cash equivalents to meet operating capital requirements.

Mitigation Strategies

• Utilizing advanced waste gas treatment equipment and technologies.
• Developing emergency response plans for natural disasters.
• Implementing energy-efficient cooling technology and systems.
• Paying close attention to changes in environmental laws, regulations, and policies.
• Boosting R&D capabilities through measures such as training and talent retention.
• Seeking additional financing to fund operations.
• Optimizing supply chain management to ensure efficient and rapid delivery of drugs.

Supply Chain Management

Supplier Audits: 16 suppliers reviewed (2023)

Responsible Procurement

• Strict preliminary reviews of suppliers’ qualification documents.
• Comprehensive assessment of suppliers’ quality management systems, production equipment, and process flows.
• Onsite audits of suppliers of key materials.
• Continuous improvement of the qualified supplier database.

Climate-Related Risks & Opportunities

Physical Risks

• Extreme weather events (damage to assets, business disruption)
• Lasting heatwave, drought (increased cooling costs)

Transition Risks

• New policies and regulations (increased compliance costs)
• Technological changes (failure to adopt low-carbon technologies)
• Market shifts (customer preference for green products)
• Reputation risks (poor performance in combating climate change)

Opportunities

• Development of energy-efficient products and technologies

Reporting Standards

Frameworks Used: ESG Reporting Guide in the Main Board Listing Rules (HKEX)

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

• Not disclosed

Not disclosed

Sustainable Products & Innovation

• Not disclosed

Awards & Recognition

• Not disclosed